KR20150093216A - 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-OS-Mal-III의 적용 - Google Patents

말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-OS-Mal-III의 적용 Download PDF

Info

Publication number
KR20150093216A
KR20150093216A KR1020157018094A KR20157018094A KR20150093216A KR 20150093216 A KR20150093216 A KR 20150093216A KR 1020157018094 A KR1020157018094 A KR 1020157018094A KR 20157018094 A KR20157018094 A KR 20157018094A KR 20150093216 A KR20150093216 A KR 20150093216A
Authority
KR
South Korea
Prior art keywords
mal
ppi
iii
dendrimer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157018094A
Other languages
English (en)
Korean (ko)
Inventor
아이다 프라니아크-피에트리가
마리아 브리스제브스카
디트마르 아페란스
바르바라 크라즈네트
Original Assignee
우니베르스테트 우쯔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우니베르스테트 우쯔 filed Critical 우니베르스테트 우쯔
Publication of KR20150093216A publication Critical patent/KR20150093216A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K47/48192—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157018094A 2012-12-06 2013-12-06 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-OS-Mal-III의 적용 Withdrawn KR20150093216A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL401936A PL234888B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PLP-401936 2012-12-06
PCT/PL2013/000163 WO2014088435A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii

Publications (1)

Publication Number Publication Date
KR20150093216A true KR20150093216A (ko) 2015-08-17

Family

ID=49955472

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157018094A Withdrawn KR20150093216A (ko) 2012-12-06 2013-12-06 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-OS-Mal-III의 적용

Country Status (9)

Country Link
US (1) US9877985B2 (cg-RX-API-DMAC10.html)
EP (1) EP2928479A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501261A (cg-RX-API-DMAC10.html)
KR (1) KR20150093216A (cg-RX-API-DMAC10.html)
AU (1) AU2013356793A1 (cg-RX-API-DMAC10.html)
CA (1) CA2893973A1 (cg-RX-API-DMAC10.html)
IL (1) IL239144A0 (cg-RX-API-DMAC10.html)
PL (1) PL234888B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088435A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL234887B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PL416636A1 (pl) * 2016-03-24 2017-09-25 Univ Łódzki Medyczne zastosowanie dendrymeru polipropylenoiminowego czwartej generacji, opłaszczonego maltotriozą

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure
PL234887B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Also Published As

Publication number Publication date
AU2013356793A1 (en) 2015-07-23
PL234888B1 (pl) 2020-04-30
CA2893973A1 (en) 2014-06-12
WO2014088435A1 (en) 2014-06-12
PL401936A1 (pl) 2014-06-09
US20150306134A1 (en) 2015-10-29
EP2928479A1 (en) 2015-10-14
US9877985B2 (en) 2018-01-30
JP2016501261A (ja) 2016-01-18
IL239144A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
Zhao et al. Sonodynamic therapy of NRP2 monoclonal antibody‐guided MOFs@ COF targeted disruption of mitochondrial and endoplasmic reticulum homeostasis to induce autophagy‐dependent ferroptosis
Wei et al. Tagitinin C induces ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal cancer cells
Liu et al. Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways
Wu et al. Regulatory mechanism of α-hederin upon cisplatin sensibility in NSCLC at safe dose by destroying GSS/GSH/GPX2 axis–mediated glutathione oxidation-reduction system
Holwell et al. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
Mameri et al. Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane
Albuz et al. Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results
Ünsal et al. The apoptotic effect of garlic (Allium sativum) derived SEVs on different types of cancer cell lines in vitro
Su et al. Roles of PTEN gene methylation in Se-CQDs induced mitochondrial apoptosis of osteosarcoma cells
Benvenuto et al. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo
Wang et al. Endoplasmic reticulum-mitochondria dual-targeting nanoplatform suppresses cancer stemness and enhances colorectal cancer immunotherapy
CN109745326B (zh) 一种包含吉非替尼和组蛋白去乙酰酶抑制剂的药物组合物,其脂质体制剂及其制药用途
Huang et al. Muscle homing peptide modified liposomes loaded with EGCG improved skeletal muscle dysfunction by inhibiting inflammation in aging mice
Chen et al. Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplatforms enhances the efficacy of checkpoint blockade immunotherapy
US9877985B2 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
KR20150099539A (ko) 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-DS-Mal-III의 적용
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
WO2020171138A1 (ja) 放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー
Donmez et al. Investigation of the Effects of Three Different Generations of Fluoroquinolone Derivatives on Erythrocyte Fragility and Hematological Parameters in Rats
US20240009212A1 (en) Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof
Huang et al. Preparation and biocompatibility evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP nanoparticles
Jakopec et al. Structurally similar diazenes exhibit significantly different biological activity
RU2810558C1 (ru) Способ подбора лекарственных средств для реализации фармакологической индукции митохондриальной дисфункции в макрофагах для противоопухолевой терапии
Joma Polyphenolic and polydendritic molecules as modulators of glioblastoma multiforme and its microenvironment
Singhal Investigation of anthracycline based topoisomerase II inhibitors in triple negative breast cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150706

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid